Q2 profitability beat and H2 launches reinforce credibility
02/08/26 -"DiaSorin’s Q2 profitability surpassed expectations. Despite weak respiratory sales and challenges in China, revenue grew by mid-single digits. All segments experienced growth, with Life Science ..."
Pages
66
Language
English
Published on
02/08/26
You may also be interested by these reports :
02/08/26
DiaSorin’s Q2 profitability surpassed expectations. Despite weak respiratory sales and challenges in China, revenue grew by mid-single digits. All ...
31/07/26
Siemens Healthineers’ Q3 sales slightly missed expectations, though profitability met forecasts. The Precision Therapy and Imaging segments reported ...
31/07/26
Amplifon’s Q2 profitability surpassed market expectations, driven by healthy top-line growth across all regions, particularly in EMEA, a key market. ...
31/07/26
Emeis’ HY26 confirms its positive trend on both operating and debt metrics. Occupancy rates caught the momentum, especially in France and Germany, ...